A 1-month trial comparing topiramate 100 mg/day versus phenytoin (1000 mg on day 1, 300 mg/day maintenance) in 261 patients with new-onset epilepsy has found that the two treatments are comparable. The primary objective of non-inferiority could not be established (Ramsay et al. Epilepsia 2010; 51: 1970-1977).